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Synopsis
CD44v6, a member of the CD44 family of transmembrane glycoproteins is a co-receptor for two receptor tyrosine
kinases (RTKs), Met and VEGFR-2 (vascular endothelial growth factor receptor 2). CD44v6 is not only required for
the activation of these RTKs but also for signalling. In order to understand the role of CD44v6 in Met and VEGFR-2
activation and signalling we tested whether CD44v6 binds to their ligands, HGF (hepatocyte growth factor) and VEGF
(vascular endothelial growth factor), respectively. FACS analysis and cellular ELISA showed binding of HGF and VEGF
only to cells expressing CD44v6. Direct binding of CD44v6 to HGF and VEGF was demonstrated in pull-down assays
and the binding affinities were determined using MicroScale Thermophoresis, fluorescence correlation spectroscopy
and fluorescence anisotropy. The binding affinity of CD44v6 to HGF is in the micromolar range in contrast with the
high-affinity binding measured in the case of VEGF and CD44v6, which is in the nanomolar range. These data reveal a
heparan sulfate-independent direct binding of CD44v6 to the ligands of Met and VEGFR-2 and suggest different roles
of CD44v6 for these RTKs.
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INTRODUCTION
Receptor tyrosine kinases (RTKs) are single-pass transmembrane
proteins with an extracellular ligand binding domain and an in-
tracellular catalytic domain. They are thought to get activated by
ligand-induced dimerization (or more generally oligomerization)
of their ectodomains, facilitating trans-phosphorylation of their
tyrosine kinase domains. However, increasing evidence show that
the activation process of RTKs is not only dependent on ligand
binding but requires in addition the contribution of cell adhesion
molecules (CAMs) (reviewed in [1]). These CAMs act in most
cases as co-receptors providing a plethora of functions to the
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RTKs. They participate in the activation process by clustering
the ligand thereby facilitating its binding to RTKs or by promot-
ing dimerization. They also take part in the signalling process
by amplifying the signals emanating from the RTKs and even
participate in the internalization process.
The first described co-receptors for RTKs are the heparan
sulfate proteoglycans (HSPGs) that act as low-affinity receptor
for the fibroblast growth factor receptor (FGFR). These low-
affinity receptors foster clustering of growth factors thereby con-
centrating the ligands in the vicinity of the high affinity receptor.
The studies of Yayon et al. [2] demonstrated a requirement of
heparin/HS for FGFR activation. Additional data showed that
the FGF-2 (fibroblast growth factor 2)/FGFR-1 interaction as
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well as the FGF-2-induced signalling is stimulated by HSPGs
such as syndecans and glypicans [3,4]. Syndecan-2 on human
macrophages stimulates FGF-2-mediated proliferation [5], and
glypican-1 activates FGF-2 signalling [6,7]). HSPGs stabilize
the FGF:FGFR dimers [8]. Heparin/heparan sulfate (HS) binds
to a positively charged canyon formed by the two FGF receptors
associated in the dimer and the adjoining bound FGF molecules
[9].
In the case of both VEGFR-2 (vascular endothelial growth
factor receptor 2) and Met, prominent RTKs involved in an-
giogenesis and metastasis, CD44v6 is one of the best character-
ized co-receptors (reviewed in [10]). CD44v6, a non-heparin/HS
sulfated member of the CD44 family of transmembrane gly-
coproteins [11] is required for Met and VEGFR-2 activation and
signalling in several cancer cell lines and primary cells. More
precisely, the ectodomain of CD44v6 takes part in the activation
process whereas the cytoplasmic domain of CD44 is involved
in signalling (reviewed in [12]). CD44v6 controls Met internal-
ization and is also co-internalized with Met upon induction by
HGF (hepatocyte growth factor) [13]. Ala-scan mutation of the
CD44v6 exon sequence revealed the importance of three amino
acids in the v6 exon sequence for the co-receptor function of
CD44v6 for Met [14]. Mutation of these sequences correspond-
ing to EWQ in rat, RWH in human and GWQ in mouse CD44v6
prevented Met activation. Small peptides (v6 pep) ranging from
5 to 14 amino acids covering these three essential amino acids
inhibited Met and VEGFR-2 activation and signalling, and con-
sequently tumour angiogenesis [15].
VEGFR-2 also recruits another co-receptor, namely neuropilin
(NRP-1/2), thereby promoting a full-blown angiogenic response
(reviewed in [16]). In that case, VEGF (vascular endothelial
growth factor) is able to bridge VEGFR-2 to NRP-1/2 by bind-
ing both molecules simultaneously. Neuropilin is a low-affinity
receptor for VEGF that has essential functions in VEGF-induced
angiogenesis. NRP-1 also takes part in the trafficking of VEGFR-
2 thereby controlling signalling [17]. Indeed, association of
VEGFR-2 with NRP-1 induces p38 MAPK signalling. CD44v6
is therefore an additional co-receptor of VEGFR-2 that is essen-
tial for the activation process and signalling in several primary
endothelial cells [15]. Its precise molecular mechanism of action
is still elusive.
Many open questions also remain concerning the activa-
tion process of Met and the exact molecular contribution of
CD44v6. Upon HGF induction a ternary complex between
Met, HGF and CD44v6 could be detected in several cell lines
[13,18,19].
The interactions between HGF, Met and CD44v6 on the one
hand and VEGF, VEGFR-2 and CD44v6 on the other hand need
to be further characterized. In the present paper, using FACS and
cellular ELISA we show binding of HGF and VEGF only to
cells expressing CD44v6. Furthermore, pull-down assays reveal
a direct binding between these entities. The binding affinities
of purified CD44v6 ectodomain for VEGF and HGF respect-
ively were measured using MicroScale Thermophoresis (MST),




Human umbilical vein endothelial cells (HUVEC; PromoCell,
Heidelberg, Germany) were grown in Endothelial Cell Growth
Medium complemented with Supplement Mix (PromoCell). The
human embryonic kidney cells (HEK293T; ATCC, Wesel, Ger-
many), the human colon adenocarcinoma cells (HT29), a gift
from Alain Zweibaum (Institute National de la Sante et de la
Recherche Medicale, Paris, France) and the human cervix car-
cinoma cells (HeLa; ATCC) were grown in Dulbecco’s Modified
Eagle’s Medium (DMEM; Invitrogen, Karlsruhe, Germany) sup-
plemented with 10 % FBS (FBS Gold; PAA Laboratories). The
rat pancreatic carcinoma cells BSp73AS (AS) and its transfect-
ant BSp73ASs6 (ASs6) were already described [18] and grown
in RPMI (Invitrogen) plus 10 % FBS. The human ductal breast
epithelial tumour cell lines (T47D and T47D/Met/T47D2A) were
a gift from Morag Park (McGill University, Montreal, Canada)
and cultured in DMEM supplemented with 10 % FBS.
Reagents
The antibodies used in the present study were directed against
rat CD44v6 (1.1ASML, described in [20]) and human CD44v6
(VFF18; Boehringer Ingelheim), Erk-1 (K-23; Santa Cruz),
phospho-p44/42 MAPK (Thr202/Tyr204; Cell Signaling Tech-
nology), penta-His (Qiagen), human HGF (AF-294-NA; R&D
Systems), rat Met (B2; Santa Cruz), human Met (25H2; Cell Sig-
naling Technology) phospho-Met (Tyr1234/1235; Cell Signaling
Technology), human TGF-α (transforming growth factor alpha;
Peprotech), VEGFR-2 (A3; Santa Cruz) and human VEGF-A165
(VEGF165) (AF-293-NA; R&D Systems). The secondary anti-
bodies labelled with horseradish peroxidase (HRP) were from
Dako, the phycoerythrin (PE)-labelled antibody from Thermo
Scientific and the FITC–streptavidin from Invitrogen. The human
HGF was a generous gift from Ermanno Gherardi (University of
Pavia, Pavia, Italy). Human VEGF165 and human TGF-α were
from Peprotech. The peptides have already been described in
[14] and their sequences are: rat CD44v6 5mer – NEWQG, rat
CD44v6 14mer – KEKWFENEWQGKNP, human CD44v6 5mer
– NRWHE, human CD44v6 14mer – KEQWFGNRWHEGYR,
mouse CD44v6 5mer – NGWQG and mouse CD44v6 14mer –
QETWFQNGWQGKNP.
Constructs
The rat CD44v6 expression construct used for protein expression
and purification of the CD44v6 ectodomain was kindly provided
by Kurt Ballmer-Hofer (Paul Scherrer Institute, Villigen, Switzer-
land). Here the extracellular part of the rat CD44v6 sequence was
cloned in-frame with a hexahistidine sequence at the C-terminal
end of the CD44 sequence into a pcDNA3.1( + ) plasmid. The
human CD44s ectodomain was cloned in the same way into the
pcDNA3.1( + ) vector.
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The human Met928 construct, comprising almost the entire
extracellular sequence of Met, was expressed in CHO Lec8 cells.
The cells were cultured in FCS-free medium and secreted the
C-terminally His-tagged Met928 protein into the medium for the
following NiNTA superflow (Qiagen) affinity chromatography
protein purification. The conditions have been described in detail
in [21,22].
The VEGFR-2 expression construct has been previously de-
scribed [15]. The VEGFR-2 expression plasmid pBE hVEGFR-2
was derived from the pEGFP-C1 vector from Clontech by in-
troducing the sequence encoding the human VEGFR-2 with
the PCR subcloning method to remove the GFP reading
frame with the forward primer: GCTCTTCGGGGAGCAGCG-
ATGGAGAGCAAGGTGCTGCTG and the reverse primer:
GGAGGTTTTTTAAAGCAAGTAAAACCTTTATCACAG-
ATCCTCTTCTGAGATGAG.
The expression vector secreting the soluble part of CD44
(either CD44s or CD44v4–715) used in the FACS experiments
has been described in Orian-Rousseau et al. [18]. In brief, a
CD44s or a CD44v4-v715-human Fc fusion was cloned in the
CDM8 vector.
Expression and purification of CD44 proteins
The CD44 constructs (rat CD44v6 and human CD44s) were tran-
siently transfected in HEK293T cells using 20 μg/ml branched
polyethylenimine (Sigma-Aldrich). Two days after transfection
sodium butyrate was added to a final concentration of 6 mM. Four
days post transfection the supernatant was collected and concen-
trated via a 10 kDa cut off membrane (Sartorius) using a Sartocon
ultrafiltration device (Sartorius) and diluted 1:10 in loading buf-
fer (50 mM HEPES, 260 mM NaCl and 10 mM imidazole, pH 7)
and again concentrated via ultrafiltration. The proteins were pur-
ified on a nickel-nitrilotriacetic acid (Ni-NTA) column (20 ml
HisPrep FF 16/10 column; GE Healthcare) and eluted with a
linear gradient of an elution buffer (50 mM HEPES, 260 mM
NaCl and 1 M imidazole, pH 7). The fractions from purifica-
tion were pooled, concentrated and rebuffered in storage buffer
(50 mM HEPES, 150 mM NaCl and 5 % glycerol, pH 7.5) via
ultrafiltration (Vivaspin 10 kDa cut off; Sartorius). Proteins were
then subjected to Western blot analysis.
Activation of Met and Erk
ASs6 cells were serum-starved for 24 h, and then induced with
20 ng/ml HGF for 5 min at 37 ◦C. Where indicated, the cells were
treated with different concentrations of CD44s ectodomain and
CD44v6 ectodomain for 5 min at 37 ◦C prior to induction. Activ-
ated Met and Erk was determined using Western blot analysis as
previously described [15].
Fluorescence-activated cell sorting
Binding of human HGF and human VEGF165 to cells was meas-
ured by FACS analysis. Cells were seeded at a density of 5×105
cells in 5 cm plates. For the HGF binding assay in presence of
the CD44v6 and CD44s ectodomain, the T47D and T47D/Met
cells were transfected with the corresponding expression vec-
tors using Lipofectamine (Invitrogen) according to the manufac-
turer’s protocol. On the next day cells were serum-starved for
24 h. For blocking experiments serum-starved AS, ASs6, T47D
and T47D/Met cells were incubated either with the respective
species-specific CD44v6 antibody (100 μg/ml), v6 or control
peptide (100 ng/ml) for 1 h at 4 ◦C and then induced with 20 ng/ml
biotinylated HGF for 1 h at 4 ◦C. Biotinylation of HGF was per-
formed as described in [18]. After two washing steps using PBS
(Cat. #14190; Invitrogen) the cells were detached from the plates
using PBS supplemented with 5 mM EDTA and resuspended in
PBS containing 3 % FBS. The cells were incubated with FITC–
streptavidin (1 μg/ml) for 30 min on ice followed by three final
washing steps and resuspension in PBS. The fluorescence was
analysed in a FACScan flow cytometer (Becton Dickinson). For
the VEGF binding assay serum-starved HUVEC and ASs6 cells
were incubated with the respective species-specific v6 or control
peptide as described above followed by induction with 20 ng/ml
of VEGF165 for 1 h at 4 ◦C. After washing and detaching the cells
were incubated with an antibody against VEGF165 (10 μg/ml)
for 1 h at 4 ◦C. Following three washing steps the cells were in-
cubated with an anti-goat IgG (PE-conjugate) for 30 min at 4 ◦C
protected from light, washed, resuspended in PBS and analysed
in the FACScan flow cytometer.
Cellular enzyme-linked immunosorbent assay
Cells were seeded in 96-well plates at a concentration of 4x104
cells per well. AS and ASs6 cells were transfected with a VEGFR-
2 expression vector using FuGene (Promega) according to the
manufacturer’s protocol. On the next day cells were serum-
starved for 24 h. After starvation cells were washed twice with
PBS and blocked for 1 h at room temperature with 100 μl/well
of PBS plus 5 % BSA. Where indicated, cells were treated with
100 ng/ml rat v6 peptide or 100 ng/ml control peptide for 1 h
at 4 ◦C prior to the induction with 20 ng/ml biotinylated human
HGF, 20 ng/ml biotinylated human VEGF165 (as performed for
HGF) or 20 ng/ml biotinylated soybean trypsin inhibitor (used
as negative control) (R&D Systems) for 1 h on ice. The cells
were then incubated with an avidin–HRP conjugate (Abcam) for
30 min at 4 ◦C protected from light. Cells were washed twice with
PBS and the ABTS solution (Roche Diagnostics) was added for
45 min at room temperature. The absorption at 415 nm was de-
termined with an ELISA reader EXL 808 (Biotek). Experimental
data of the negative controls (biotinylated soybean trypsin inhib-
itor) were directly subtracted from the experimental data of the
biotinylated human HGF and VEGF165.
Liquid chromatography time-of-flight spectrometry
CD44v6 was digested with trypsin and analysed using ultra-high
performance liquid chromatography tandem mass spectrometry
(UHPLC–MS/MS, Agilent Technologies). 2 μl of each sample
(corresponding to 1 μg) were injected. The chromatographic sep-
aration was performed using reverse-phase chromatography with
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water plus 0.1 % formic acid as solvent A and acetonitrile plus
0.1 % formic acid as solvent B. The gradient consisted of an
isocratic step for 0.5 min at 3 % solvent B, followed by linear
gradients from 3 % to 60 % solvent B over 5.5 min and from
60 % to 100 % B over 1 min. The column was washed at 100 %
B for 1 min followed by a linear gradient from 100 % to 3 % B
within 0.1 min and 1.9 min re-equilibration time. The overall run-
ning time was 10 min at a flow rate of 0.5 ml/min and the column
was thermostatted at 20 ◦C. The quadrupole-time-of-flight mass
spectrometer was tuned and calibrated in 2 GHz “extended dy-
namic range mode” for a mass range up to 3200 m/z and operated
in data-dependent “Auto MS/MS” mode. Positive electrospray
ionization was carried out using a capillary voltage of 4500 V
and a fragmentor voltage of 175 V. Nitrogen was used as drying
gas with 8 l/min at 300 ◦C and sheath gas respectively with 11
l/min at 350 ◦C, nebulizer pressure was 35 psig. Data-dependent
data acquisition was carried out using “Auto MS/MS” mode.
Alternating acquisitions in MS and MS/MS were carried out de-
tecting both intact peptide masses and peptide fragment masses
respectively after collision-induced dissociation (CID) using ni-
trogen as a collision gas. The scan rate for both MS and MS/MS
was set to 5 Hz, the collision energy was ramped depending on
precursor m/z with an offset of 3 V and a slope of 4 V/100 Da
(Dalton). The precursor charge state preference was 2 > 3 > 4 or
higher > 1 > unknown. A maximum of 2 precursors was isolated
and fragmented within each cycle using both dynamic exclusion
after 2 spectra and release after 0.5 min and static exclusion for
precursors with 100–300 m/z and 900–3200 m/z.
Data interpretation was carried out by matching the obtained
MS and MS/MS spectra against the hypothetical “in-silico-
digest” of CD44v6 protein sequence. Herewith, no missed cleav-
age and post-translational modification such as glycations were
taken into consideration and only masses within a mass tolerance
of 10 ppm for MS and 50 ppm for MS/MS were accepted.
Scattering assay
Cells were seeded in 24-well plates at a density of 4×104 cells per
well and serum-starved the next day for 24 h. Where indicated
25 μg/ml human CD44s ectodomain or 25 μg/ml rat CD44v6
ectodomain were applied and incubated for 5 min at 37 ◦C prior
to induction with 20 ng/ml HGF. 24 h later cells were observed
with the Axiovert 40c Zeiss microscope (10× objective, Carl
Zeiss AG) and pictures were taken using a PowerShot S620 digital
camera (Canon).
In vitro monolayer wound closure assay
Cells were seeded in 12-well plates at a density of 1.5×105
cells per well and serum-starved the next day for 24 h. After
starvation a scratch was made into the confluent cell layer using
a sterile pipette tip. The medium was changed and replaced by
fresh medium or medium containing 25 μg/ml human CD44s
ectodomain or 25 μg/ml rat CD44v6 ectodomain. After 5 min
at 37 ◦C, induction with 20 ng/ml HGF was performed. Pictures
were taken directly after the scratch and 24 h after induction
using a PowerShot S620 digital camera (Canon). The computer
program ImageJ (National Institutes of Health) was used for
quantitative evaluation. The area covered by cells that migrated
into the wound was quantified.
Nickel pull-down assay
For the pull-down assays Ni-NTA beads (Qiagen) were used.
30 μl of the Ni-NTA beads were washed once in pull-down (PD)
buffer (50 mM HEPES, 150 mM sodium chloride and 100 mM
imidazole, pH 7.5) and resuspended in it. 0.5 μg of the ectodo-
mains were added together with 0.5 μg of the different growth
factors (HGF, VEGF165 and TGF-α) and incubated on a spinning
wheel for 2 h at 4 ◦C. After incubation the beads were washed
three times with the PD buffer, the supernatant was removed
and the nickel-bound proteins were subjected to Western blot
analysis.
MicroScale Thermophoresis
10 μM of HGF, VEGF165 and CD44v6 ectodomain were labelled
with a red fluorescent dye (NT-647) using the Protein Labeling
NHS RED Kit (NanoTemper Technologies). 10 μM of proteins
were incubated with 30 μM of the fluorophore NT-647 for 30 min
at room temperature protected from light. Meanwhile a gravity
flow column was equilibrated with 10 ml PBS. After incubation
the labelled protein was loaded on the gel filtration column to
separate free dye from labelled protein. 10 nM of fluorescently
labelled protein (HGF, VEGF165 and CD44v6 ectodomain) was
added to a serial dilution of unlabelled protein (serial dilutions:
0.8 nM to 27 μM of CD44v6 or CD44s, 0.4 nM to 7 μM of
Met928 and 2.1 nM to 70 μM of TGF-α and 0.1 nM to 10 μM
of CD44 v6 peptide). The samples were loaded into hydrophilic
capillaries (NanoTemper Technologies, reference K004). Meas-
urements were performed in the Monolith NT.115 at 22 ◦C in
PBS plus 1 % BSA by using 50 % LED power and 80 % IR-laser
power. Data were analysed using NanoTemper Analysis soft-
ware v.1.4.23 and plotted using the OriginPro v.8.6 software from
OriginLab.
Fluorescence correlation spectroscopy
The FCS measurements were performed using either a commer-
cial ConfoCor2 fluorescence correlation spectrometer (Carl Zeiss
AG) or a custom-built confocal setup. The custom-built setup
was equipped with a 640 nm diode laser (Cube 640; Coherent).
The laser beam was reflected into a water immersion object-
ive (UPLSAPO, 60x, NA 1.2; Olympus) by a dichroic mirror
(650DCXR; AHF Analysentechnik). The emission light passed
the dichroic mirror and was focused with an achromatic lens (f =
100 mm) onto a pinhole (100 μm). A second lens (f = 100 mm)
parallelized the light again. Passing a bandpass filter (700/75 ET,
AHF Analysentechnik), the emission light was separated by a
50/50 beamsplitter (AHF Analysentechnik). Two convex lenses
(f = 25.5 mm) focused the emission light on to the active area
of two single-photon APDs (SPCM-AQRH-14; PerkinElmer). A
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Flex03LQ correlator card (correlator.com) cross-correlated the
fluorescence signal. In the ConfoCor2, the 633 nm laser was
used to excite the fluorophores in the sample. A water immersion
objective (40×, NA 1.2 C-Apochromat) focused the laser light
into the sample.
HGF, VEGF165 and TGF-α were labelled with ATTO 647N
NHS ester (ATTO-TEC) according to the manufacturer’s pro-
tocol. For FCS experiments, samples were prepared in PBS buf-
fer containing 0.05 % Tween-20 (PBST). Additionally, a protocol
using poly-L-lysine polyethylene glycol (PLL-PEG) was estab-
lished to prevent glass adsorption. Here, coverslips (Ø 19 mm)
were cleaned for 20 min by sonification in isopropyl alcohol,
washed in water, and dried with nitrogen. After 10 min plasma
cleaning, 10 μl 1 mg/ml PLL-PEG in bidistilled water were
dropped on to a coverslip and a second coverslip was placed
on top of it. After 1.5–2 h incubation, coverslip sandwiches were
separated in bidistilled water and dried with nitrogen.
For sample preparation, the unlabelled binding partner was
added in different concentrations in the range from 0.1 nM to
20 μM to the fluorescently labelled protein (1–5 nM). The com-
plex formation was allowed to occur for at least 3 h at room
temperature. Each measurement was done at a constant imaging
depth of 80 μm (custom-built setup) or 200 μm (ConfoCor2)
from the glass surface. For each measurement, the fluorescence
signal was recorded for 5 min. All measurements were carried
out at 20 ◦C.
Diffusion times were determined by fitting with a 2D diffu-
sion model as described elsewhere [23]. Complete binding curves
were determined by plotting the diffusion times at different con-
centrations of the unlabelled protein. Fitting with a 1:1 binding
model allows estimation of the dissociation constant Kd.
Fluorescence anisotropy
A spectrofluorimeter (SLM 8000, SPEX, USA) in the T-format
configuration was used to measure steady-state FA (r). The excit-
ation wavelength was set at 580 nm for HGF tagged with the red
fluorescent dye (NT-647) using the Protein Labeling NHS RED
kit (NanoTemper Technologies) as described for MST. The emit-
ted light was monitored with a 600 nm long pass filter (Wratten
29, Kodak). The labelled HGF protein was titrated with increas-
ing concentrations of CD44v6 or CD44s. A home-built device
ensured the automatic rotation of the excitation polarizer, al-
lowing continuous measurement of the anisotropy during 120 s.
Temperature was fixed at 20 ◦C. Anisotropy values were calcu-
lated and recorded with the Bio-Kine program (Bio-Logic). As
the intensity of fluorescence of the labelled HGF was found to be
not affected by the binding process, the anisotropy r of HGF of
can be expressed by:




⎝ (1 + K a × (n × Pt + Lt )) −
√
(1 + K a × (n × Pt + Lt ))2 −
(
4 × K a2 × n × Pt × Lt
)
2 × K a × Lt
⎞
⎠
where Lt and L are respectively the total and free concentrations
of CD44v6 or CD44s, Pt is the total concentration of HGF, n
is the binding stoichiometry of the complex, rf and rb are the
anisotropy of the free and fully bound HGF protein, respectively.
RESULTS
Binding of HGF and VEGF to cells detected only in
CD44v6-expressing cells
Since the CD44v6 ectodomain is required for Met activation (re-
viewed in [12]), we hypothesize that its role in Met activation
is linked to its ability to bind HGF. In order to test whether
CD44v6 is involved in the binding of HGF to Met-positive cells,
we performed FACS analyses. Binding of biotinylated HGF to
BSp73ASs6 (ASs6) cells that express CD44s, the smallest CD44
isoform, CD44v6 and Met (Supplementary Figure S1A) and in
which Met can be activated [14] was measured by FACS us-
ing streptavidin. The Bsp73AS (AS) cells that express Met and
CD44s but do not express CD44v6 ([14]; Supplementary Figure
S1A) were used as control. In these control cells, Met activation
was either low or undetectable. The FACS analysis showed that
HGF bound to ASs6 cells but not to AS cells (Figure 1A). This
binding was dependent on CD44v6 as blocking reagents such as
the CD44v6 antibody (α-CD44v6) or a CD44v6 specific peptide
(v6 pep) completely abrogated this binding. In contrast, a control
peptide (ctrl pep) had no effect.
Since binding of HGF to cells could only be observed in
cells expressing CD44v6, we investigated whether CD44v6 alone
might be sufficient for this binding. We compared the binding
of biotinylated HGF to T47D cells that do not express Met
but express CD44v6 ([24] and Supplementary Figure S1B) to
T47D/Met cells that express both proteins (Figure 1B). As expec-
ted, HGF bound to cells that express both CD44v6 and Met. This
binding was specific to CD44v6 as it could be blocked by trans-
fection of a CD44v6 ectodomain whereas transfection of a CD44s
ectodomain had no effect. Binding of HGF to T47D/Met cells
was also blocked by means of a CD44v6 antibody (α-CD44v6)
and the v6 peptide. Surprisingly however, binding of HGF was
also observed in the absence of Met in T47D cells. Again, this
binding was inhibited upon transfection of the CD44v6 ectodo-
main as well as pre-incubation with the CD44v6 antibody and
the v6 peptide but not by transfecting the CD44s ectodomain
(Figure 1B).
CD44v6 can also act as a co-receptor for VEGFR-2 [15].
Therefore, similar experiments were performed using VEGF165,
a member of the VEGF family inducing the VEGFR-2 receptor.
Using FACS, we tested whether the binding of VEGF165 to
VEGFR-2 positive cells was dependent on CD44v6 using an
antibody against VEGF (Figure 1C). HUVECs that express
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Figure 1 CD44v6 is required for binding of HGF and VEGF to cells
(A) Serum-starved Bsp73AS (AS) or Bsp73ASs6 (ASs6) cells were incubated with a CD44v6 antibody (1.1ASML) [20],
a v6 peptide (14mer) [14] or a control peptide prior to induction with biotinylated HGF and subsequent detection of
binding using FITC–streptavidin. All samples were analysed in a FACScan flow cytometer. The FITC–streptavidin negative
control is shown in blue, HGF-induced samples either non-treated or treated with CD44v6-specific blocking reagents are
shown in green. Representative pictures from one experiment are shown. Three independent experiments per condi-
tion were performed giving the same results. (B) Serum-starved T47D and T47D/Met cells were pretreated either with
a CD44v6 antibody (VFF18), or a v6 peptide (14mer) prior to induction with biotinylated HGF. Expression of CD44v6 and
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CD44v6 [15] and VEGFR-2 were used. As expected, VEGF165
could bind to HUVECs and this binding could be blocked by
means of the v6 peptide whereas the ctrl peptide had no effect
(Figure 1C). Interestingly, VEGF165 was also able to bind to
ASs6 cells (Figure 1C) that do not express VEGFR-2 but express
CD44v6 (Supplementary Figure S1C).
To further study the involvement of CD44v6 in the bind-
ing of HGF to cells, we performed a cellular ELISA. In this
experiment, AS, ASs6 or HT29 cells were seeded into 96-
well plates (Figure 2A, left panel). The binding of biotinylated
HGF to these cells was monitored using an avidin–HRP con-
jugate. A clear binding of HGF to ASs6 cells expressing Met
and CD44v6 was observed. In contrast, no binding of HGF
to cells expressing Met but no CD44v6 (AS) could be detec-
ted. The control wells were not coated with cells and the un-
specific binding of HGF to the plastic surface was evaluated.
HGF could bind to HT29 cells that were used as a positive
control. Indeed, in HT29 cells that express both CD44v6 and
Met, the co-receptor function of CD44v6 for Met has extensively
been shown [18,25]. We also detected binding of VEGF165 to
ASs6 cells expressing CD44v6 and transfected with VEGFR-
2 whereas AS cells expressing only VEGFR-2 (Figure 2B, left
panel) showed a binding similar to uncoated control wells. In
HUVECs used here as a positive control, binding of VEGF165
was detected. The co-receptor function of CD44v6 for VEGFR-2
was shown in these cells [15] and they express both CD44v6 and
VEGFR-2.
Both in the case of HGF and VEGF165, the v6 peptide abrog-
ated binding of the growth factors to ASs6 cells (Figures 2A and
2B right panels).
Taken together the FACS analysis and the cellular ELISA show
that both HGF and VEGF165 bind only to CD44v6-expressing
cells. In addition, in the case of Met and VEGFR-2, the FACS
analysis revealed that the ligands are able to bind to cells even in
the absence of their authentic receptor.
A purified CD44v6 ectodomain
inhibits HGF-induced migration and scattering
The preferential binding of HGF and VEGF to cells expressing
CD44v6 suggests a direct interaction between CD44v6 and these
growth factors. In order to test whether CD44v6 directly binds to
HGF and VEGF and to measure binding affinities, we produced
the rat CD44v6 ectodomain in HEK293T cells (Supplementary
Figure S2). The hexahistidine-tagged CD44v6 ectodomain was
purified by means of IMAC (immobilized metal ion affinity chro-
matography). The different fractions were screened in Western
blot analysis with specific antibodies against CD44v6 and penta-
histidine (His) (Supplementary Figure S2A). To confirm the
CD44v6 sequence, the protein was digested with trypsin and ana-
lysed with UHPLC–MS/MS (Supplementary Figure S2B). Figure
S2C lists all identified peptide sequences and their corresponding
measured and theoretical masses and the calculated mass error.
Since it was shown that three amino acids (EWQ) in the region
of the variable exon 6 are essential for the function of CD44v6 as
a co-receptor for Met [14] the peptide sequence containing these
amino acids (highlighted in green) was further analysed with
spectral interpretation of peptide fragments induced by CID. The
peptide sequence WFENEWQGK could be confirmed via intact
peptide mass spectra across two charge states (z = 1 and z = 2) and
via their series of typical fragment series shown with a and y series
(Supplementary Figure S2D).
In order to test if the CD44v6 purified ectodomain was still
active after the different purification steps, we tested its abil-
ity to block HGF-induced Met activation and HGF-induced
scattering and migration in a monolayer-wounding assay (Fig-
ure 3). The transfected v6 containing CD44 ectodomain has
been shown to compete with endogenous CD44v6 preventing
the activation of Met [18]. Increasing amounts of CD44s ecto-
domains as well as CD44v6 ectodomains were added for 5 min
to ASs6 cells prior to HGF induction and the activation of both
Met and Erk was measured (Figure 3A). No effect on Met and
Erk activation was observed with the CD44s ectodomain. In
contrast, phosphorylation of Met and Erk decreased in a con-
centration dependent manner upon treatment with the CD44v6
ectodomain.
HGF induces dissociation of cells, epithelial to mesenchymal
transition and enhanced migration, a process called scattering (re-
viewed in [26]). We tested the effect of the CD44s and CD44v6
ectodomains on HGF-induced scattering (Figure 3B). HT29 cells
were incubated with the CD44s and CD44v6 ectodomains prior
to HGF induction. Cells were observed 24 h after HGF treat-
ment. Scattering was blocked by means of the CD44v6 ec-
todomain whereas no inhibitory effect was observed with the
CD44s ectodomain. A migration assay was also performed.
The migration of HeLa cells was measured in the presence or
CD44s.ectodomains (labelled as Ecd) was achieved by transfection of the expression constructs using Lipofectamine.
The cells were then subjected to FACS analysis 48 h after transfection. Binding of biotinylated HGF was detected using
FITC labelled streptavidin. All samples were analysed in a FACScan flow cytometer. Cells exclusively incubated with
FITC–streptavidin were used as a negative control (purple). Cells treated with HGF alone, or pretreated with the peptides,
antibody or transfected with the ectodomains are represented in green. Representative pictures from one experiment are
shown. Three independent experiments were performed giving the same results. (C) Serum-starved HUVEC and ASs6 cells
were pre-incubated either with a v6 peptide (5mer) [14] or a control peptide as indicated and induced with VEGF165. Binding
of VEGF165 to the cells was detected by means of a specific antibody against VEGF and a secondary PE-labelled antibody
and subsequently analysed in a FACScan flow cytometer. Cells exclusively incubated with the PE-labelled antibody were
used as a negative control (purple). Cells treated with VEGF165 or additionally pre-incubated with the peptides and probed
with the antibodies are represented in green. Representative pictures from one experiment are shown. Three independent
experiments were performed giving the same results.
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Figure 2 CD44v6 is required for binding of HGF and VEGF to cells
(A) For the cellular ELISA serum-starved AS, ASs6 and HT29 cells were induced with biotinylated HGF. The binding of
the growth factor to the cells was detected by means of an avidin–HRP conjugate and ABTS solution and subsequently
analysed in an ELISA reader. Experimental data are reported as mean +− S.D. of three independent experiments (*P<
0.05, **P< 0.005; Student’s t-test). ASs6 cells were in addition treated with a v6 (5mer) and a control peptide as
indicated and induced with biotinylated HGF. (B) The AS and ASs6 cells were transfected with a VEGFR-2 expression
construct using FuGene. 48 h after the transfection the cellular ELISA was performed with AS, ASs6 and HUVEC cells as
described above and the cells were induced with biotinylated VEGF165.
absence of the CD44v6 and CD44s ectodomains using
monolayer-wounding assays (Figure 3C). HGF clearly induced
migration of HeLa cells and closure of the wound in control
plates. This effect was completely blocked by treatment of cells
with the CD44v6 ectodomain whereas the CD44s ectodomain
showed no effect.
Thus the monitoring of activation of Erk and Met as well as the
scattering and the migration assays indicate that the CD44v6 ec-
todomain is functional and can be further used to study a potential
direct binding to HGF and VEGF.
Direct binding of the CD44v6 ectodomain to HGF
and VEGF
We then tested whether the purified CD44v6 ectodomain could
directly bind to purified HGF or purified VEGF165 in a pull-down
assay (Figure 4). To this aim, purified histidine-tagged CD44v6
ectodomain was pulled down by means of nickel-coated beads
and subsequently incubated with HGF or VEGF165. TGF-α was
used as a negative control since we have data indicating that
the activation of EGFR by TGF-α is independent of CD44v6
(I. Morath, C. Jung and V. Orian-Rousseau, unpublished data).
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Figure 3 The CD44v6 ectodomain is functional after the IMAC purification
(A) ASs6 cells were serum-starved, incubated with different concentrations of the CD44 ectodomains (labelled as Ecd)
as indicated and induced with HGF. The cell lysates were separated by SDS-PAGE and subjected to Western blot analysis
for detection of phosphorylated Met (P-Met) and phosphorylated Erk (P-Erk). For the loading control, the membrane was
stripped and re-probed with specific antibodies against Met and Erk. The Western blots were performed at least three
times and gave similar results. A representative blot is shown. (B) HT29 cells were serum-starved, incubated with the
different CD44 ectodomains (25 μg/ml) as indicated and induced with HGF. 24 h after HGF-induction scattering of cells
was observed with the Axiovert 40c Zeiss microscope (10× objective) and pictures were taken. (C) Representative pictures
of monolayer wound assays performed with HeLa cells in the presence or absence of HGF, CD44s or CD44v6 as indicated.
Top: Representative pictures taken 24 h after monolayer wounding. The black lines indicate the wound border immediately
after monolayer wounding. Below: Quantification is represented as percentage of invaded area. Experimental data are
reported as mean +− S.D. of three independent experiments (*P< 0.05; Student’s t-test).
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Figure 4 The CD44v6 ectodomain directly binds HGF and VEGF in pull-down assays
(A–C’) The nickel pull-down assays were performed with the histidine-tagged ectodomains of CD44 (CD44s and CD44v6).
The CD44 ectodomains were coupled to Ni-NTA beads (labelled as NiB) and incubated with the growth factors HGF, VEGF165
and TGF-α as indicated. (A, B, C) Binding of the ligands to the histidine-tagged CD44 ectodomains was analysed in Western
blots by means of specific antibodies against HGF, VEGF and TGF-α. As loading controls, the respective growth factors as
well as the CD44 ectodomains were loaded directly on the gel. (A’, B’, C’) To control the equal loading of the ectodomains
the membranes were stripped and reprobed with a specific antibody against histidine for detection of the histidine-tagged
CD44 proteins. The Western blots were performed at least three times and gave similar results. A representative blot is
shown.
Blots 4A, B and C were incubated with antibodies against HGF,
VEGF and TGF-α respectively. A strong signal was detected
upon incubation of the CD44v6 ectodomain loaded nickel beads
(Ni) with HGF or VEGF165 (last lanes in Figures 4A and 4B; in-
cubation with the respective antibodies as indicated). In contrast,
no such signal was seen in the case of TGF-α in the presence
of nickel beads and of the CD44v6 ectodomain (Figure 4C). No
signal was observed when HGF, VEGF165 or TGF-α was incub-
ated with the nickel beads alone (2nd lane in blots 4A, 4B and
4C, respectively) or with CD44s together with nickel beads (5th
lane in blots 4A, B and C, respectively). Also the CD44v6 ecto-
domain alone or in the presence of nickel beads gave no signal in
the HGF, VEGF and TGF-α blots (6th and 7th lane in blots 4A, B
and C, respectively) similarly to the CD44s ectodomain (3rd and
4th lane in blots 4A, 4B and 4C, respectively). The growth factors
HGF, VEGF165 and TGF-α were loaded as controls directly on
the gel in the first lane of blots 4A, B and C, respectively. In
conclusion, a direct binding of HGF as well as VEGF165 to the
CD44v6 ectodomain could be detected by means of pull-down
assays. No binding of any growth factor was observed with the
CD44s ectodomain. No binding was detected between TGF-α
and the CD44v6 ectodomain. The same blots were also incub-
ated with a penta-his antibody (Figure 4, lower blots A’, B’ and
C’) to visualize the histidine-tagged CD44 (CD44s and CD44v6)
ectodomains.
CD44v6 binds to HGF with low affinity and to VEGF
with high affinity
In order to define the dissociation constant (Kd) of the binding
between HGF and the CD44v6 ectodomain as well as VEGF165
and the CD44v6 ectodomain, we used MST (Figures 5A–5D).
Compared with other methods like ELISA or SPR (surface plas-
mon resonance), MST offers the advantage that the binding is
measured in solution. No immobilization of one binding partner
is necessary. The mobility of a fluorescently labelled molecule is
measured in a microscopic temperature gradient. Fluorescently
labelled HGF or VEGF165 was incubated with serial dilutions of
the CD44v6 ectodomain. A clear binding was observed between
VEGF165 and the CD44v6 ectodomain (Figure 5A) and also
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Table 1 Overview of binding affinities as determined with MST, FCS and FA
The dissociation constants (Kd) shown are the average values of N experiments
carried out for each pair of binding partners.
Method Labelled protein Binding partner Kd N
MST HGF-NT647 CD44v6 610 +− 90 nM 5
FCS HGF-ATTO 647N CD44v6 1830 +− 60 nM 6
FA HGF-NT647 CD44v6 3700 +− 600 nM 3
MST HGF-NT647 CD44s 1300 +− 300 nM 3
FCS HGF-ATTO 647N CD44s 5000 +− 3000 nM 1
FA HGF-NT647 CD44s 10000 +− 8000 nM 2
MST VEGF165-NT647 CD44v6 51 +− 9 nM 3
FCS VEGF165-NT 647 CD44v6 200 +− 40 nM 2
FCS VEGF165-ATTO 647N CD44v6 65 +− 8 nM 2
MST VEGF165-NT647 CD44s No fit 3
FCS VEGF165-ATTO 647N CD44s 1300 +− 600 nM 1
MST CD44v6-NT647 TGF-α No fit 3
MST CD44v6-NT647 Met928 No fit 2
between HGF and the CD44v6 ectodomain (Figure 5C). The Kd
for the binding of HGF to CD44v6 was 610 +− 90 nM whereas a
substantially higher affinity of 51 +− 9 nM was observed between
VEGF165 and CD44v6. To our surprise, binding was observed
between unlabelled CD44s and the fluorescently labelled HGF
(Figure 5D) but not between CD44s and the fluorescently la-
belled VEGF165 (Figure 5B). However, no binding at all was ob-
served between TGF-α and fluorescently labelled CD44v6 (Fig-
ure 5E). No binding of Met928 to labelled CD44v6 was observed
(Figure 5F).
Two other methods, namely FCS (Figure 6) and FA (Supple-
mentary Figure S3) were used to test the binding of CD44v6 to
HGF and VEGF. In FCS, fluctuations in the fluorescence sig-
nal due to the diffusion of fluorophore-labelled proteins in and
out of the focal volume are monitored. By analysing changes
in the diffusion time, the binding affinity can be determined.
Using this well-established method, we measured the binding of
HGF-ATTO 647N and VEGF165-ATTO 647N to CD44v6 and ob-
tained dissociation constants of 1830 +− 64 (S.D.) nM and 65 +− 8
(S.D.) nM, respectively. These results and binding affinities are
consistent with the MST measurements. In the case of HGF,
CD44s was shown to bind in the same range (5000 +− 3000 nM)
as CD44v6. In contrast, the binding affinity of VEGF165 to
CD44s (1300 +− 600 nM) was significantly reduced compared
with CD44v6.
In fluorescence anisotropy, the polarized light of the fluoro-
phore emission is used to determine the binding constants.
By adding increasing concentrations of unlabelled CD44v6
to NT647-labelled HGF (Supplementary Figure S3A), we ob-
served an increase in anisotropy, indicative of the slower rota-
tion of the HGF molecules as a result of their increase in size
due to their binding with CD44v6. FA confirmed the direct
interaction between HGF and CD44v6 with about the same
low affinity (3700 +− 600 nM) as measured in FCS. An in-
creased anisotropy was also observed for CD44s (Supplementary
Figure S3B) (10,000 +− 8000 nM). The affinity is here lower than
the one measured between CD44v6 and HGF.
When looking at the measured binding affinities across all
methods (Table 1), VEGF165 shows a strong binding to CD44v6
while HGF binds with a lower affinity. The calculated binding
affinity for the CD44s ectodomain to HGF is in the same order
of magnitude as for CD44v6 but is consistently 2–3 folds lower
in all three methods.
To address the mode of action of the CD44v6 peptide used
in FACS analysis and cellular ELISA, we tested whether the
CD44v6 peptide directly binds to the CD44v6 ectodomain (Sup-
plementary Figure S4A) or HGF (Supplementary Figure S4B).
In MST, the CD44v6 peptide could bind the CD44v6 ectodomain
with a high affinity of 2.10 +− 0.2 nM. However no binding could
be detected between the CD44v6 peptide and HGF (Supplement-
ary Figure S4B).
DISCUSSION
CD44v6 has been shown to act as a co-receptor for Met and
VEGFR-2 in various types of primary cells including keratino-
cytes [18] and HUVECs [15] and in several cancer cell lines
(reviewed in [12]). The CD44v6 ectodomain is required for Met
and VEGFR-2 activation whereas the cytoplasmic domain con-
nected to the cytoskeleton through ERM proteins, allows sig-
nalling. In the present paper, FACS analysis revealed binding of
HGF and VEGF165 only to cells expressing CD44v6. HGF bind-
ing to CD44v6-expressing cells could be competed against by
addition of soluble CD44v6. The binding of VEGF165 and HGF
to cells could be blocked by v6 peptides. These data suggest
that the binding of these growth factors to CD44v6 is medi-
ated by interaction with the protein part of CD44v6 and not with
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Figure 5 The CD44v6 ectodomain directly binds HGF and VEGF in MST
(A–F) Using MST the Kd was determined whenever binding was observed (fitting curves in blue). (A) Fluorescently labelled
VEGF165 was titrated against varying concentrations of the CD44v6 ectodomain (Kd = 51 +− 9 nM) or (B) the CD44s
ectodomain. (C) Titration of serial dilutions of the CD44v6 ectodomain (Kd = 610 +− 90 nM) or (D) the CD44s ectodomain
(Kd = 130 +− 300 nM) to fluorescently labelled HGF. (E) Fluorescently labelled CD44v6 ectodomain was titrated against
serial dilutions of TGF-α or (F) against the Met ectodomain (Met928). Binding affinities were calculated from at least three
different experiments.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
12 c© 2015 Authors This is an open access article published by Portland Press Limited and distributed under the Creative Commons Attribution Licence 3.0.
CD44v6 binds to HGF and to VEGF
Figure 6 FCS binding curves of CD44 isoforms with HGF and VEGF
(A–D) Dissociation constants were determined via FCS by titrating the respective CD44 isoform against the fluorophore-la-
belled growth factor. The study on VEGF165-ATTO 647N binding to (A) CD44v6 and (B) CD44s revealed dissociation
constants of 65 +− 8 nM and 1300 +− 600 nM, respectively. The same experiment was conducted with HGF-ATTO 647N
yielding a (C) Kd = 1830 +− 60 nM for CD44v6 and (D) Kd = 5000 +− 3000 nM for CD44s.
protein-linked sugars. A complementary method, namely cellular
ELISA, confirmed these findings. Pull-down assays using puri-
fied CD44v6 ectodomain and HGF qualitatively showed a direct
interaction of these two proteins in a binary system. The same is
true for VEGF165 and CD44v6. These bindings were confirmed
and quantified by MST, FCS and FA measurements. Intriguingly,
although no binding could be observed between CD44s and HGF
in pull-down assays, a binding could be measured in solution in
MST, FCS and FA. This binding between HGF and CD44s is
consistently in all methods lower than the one measured between
CD44v6 and HGF. In the case of VEGF165, no binding to CD44s
was observed in MST whereas CD44s bound to VEGF165 with a
twenty times lower affinity as compared with CD44v6 in FCS.
Although the overall behaviour of CD44v6 as a co-receptor
for Met and VEGFR-2 is very similar, a clear difference could be
seen between the binding of CD44v6 to HGF and to VEGF. The
binding of VEGF165 to purified CD44v6 ectodomain is a high
affinity binding. This binding is specific to CD44v6 since CD44s
binds VEGF165 with a 20 times lower affinity. It is therefore pos-
sible that the binding of VEGF to CD44v6 is a crucial step in the
activation of VEGFR-2 by VEGF. Moreover, the direct binding of
VEGF165 to a non-HS form of CD44, namely CD44v6 would in-
dicate that heparin/HS, if required, is not provided by CD44. The
influence of heparin/HS on the binding of VEGF165 to VEGFR-
2 was demonstrated in endothelial cells where heparin/HS was
shown to enhance binding of 125I-VEGF165 to VEGFR-2 [27].
The neuropilins that have also been described as co-receptors for
VEGFR-2 interact with heparin/HS [27]. Sprouting angiogen-
esis is sensitive to HS degradation [28]. Moreover a model where
HSPGs acting in trans might regulate VEGFR-2 signalling was
proposed. In the same line, VEGF-dependent guidance of vas-
cular sprouts was shown to involve HSPGs [29]. Taken together,
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these data suggest a complex between CD44v6, VEGF, VEGFR-
2 and neuropilin that would promote angiogenesis.
In contrast with VEGF165, the binding affinity measured
in vitro for HGF and the CD44v6 ectodomain is in the micromolar
range. This is in contrast with the high affinity binding of HGF
to a soluble Met receptor fusion protein measured in the pico-
molar range [30] and nanomolar range [31]. More precisely it was
shown that the α-chain of HGF binds to Met with high affinity
[30] and the β-chain with lower affinity [32]. That CD44v6 binds
HGF with low affinity is particularly surprising since the bind-
ing of HGF to Met-expressing cells is strictly dependent on the
presence of CD44v6. Low-affinity binding of HSPGs to growth
factor has been shown to cluster growth factors and to increase
their local concentrations in the vicinity of their authentic re-
ceptors. The accumulation of FGF-2 close to FGFR-2 promoted
sustained activation of the FGF pathway in endothelial cells [33].
Such a low-affinity binding site has been extensively described
in the case of HSPGs such as syndecans that are essential for the
clustering of FGF-2 via heparin/HS binding and its presentation
to FGFR-1 [3]. Elimination of HS from the cell surface reduced
binding of FGF-2 to FGFR-1 [34]. However, the CD44v6 iso-
form shown to act as a co-receptor for Met does not contain exon
v3, the only known HS attachment site in CD44 [11].
Discrepancy between in vivo data measured on cells and
in vitro data obtained with purified proteins are also observed
in the case of Met. Indeed, as mentioned above purified Met
binds HGF with high affinity whereas our cellular assays suggest
that HGF does not bind Met-expressing cells in the absence of
CD44v6. These discrepancies might be due to the fact that the
in vitro binding experiments investigating the binding of HGF to
Met were performed exclusively with a purified Met ectodomain
[30,35] and not with a full-length Met molecule. Membrane-
bound Met might exhibit lower affinity for HGF than the isolated
Met ectodomain, e.g. due to an inhibitory effect of the trans-
membrane or the cytoplasmic domain. In the literature, there are
several examples of receptors, in which the cytoplasmic region
influences ligand affinity of the extracellular domain by conform-
ational coupling via the transmembrane domain. In integrins, as-
sociation of the cytoplasmic domains stabilizes the extracellular
domain in a low-affinity state [36]. Even addition of only the
transmembrane domains to a recombinant integrin ectodomain
lowered the ligand affinity [37]. In the case of epidermal growth
factor receptor (EGFR), negative cooperativity for binding of lig-
ands to the extracellular domain is only observed for the intact
transmembrane protein, but not upon deletion of the cytoplasmic
part or for the soluble ectodomain [38].
Binding of HGF to Met might depend on the association of
HGF or Met to a co-receptor such as CD44v6. However, a direct
effect of CD44v6 on Met in order to alleviate such an auto-
inhibition seems unlikely, as the interaction of the two proteins
in the cell depends on the presence of HGF. In addition, direct
contact between the purified Met928 ectodomain and CD44v6,
could not be shown by MST. Thus HGF might be required to
bridge CD44v6 and Met. Indeed, the Met/CD44v6 complexes
detected upon immunoprecipitation were obtained only in the
presence of HGF [13,18,19].
CD44s cannot act as a co-receptor for Met, cannot support the
binding of HGF to cells and cannot be pulled down with HGF.
However binding of CD44s to HGF was observed in MST, FCS
and FA. We therefore have to consider whether CD44v6 has ad-
ditional functions for Met that CD44s cannot fulfil. What other
role could CD44v6 play? CD44v6 might participate in the dimer-
ization of Met. The Met dimer structure is not known and till now
it was not possible to show how HGF can induce dimerization
of Met itself in vitro although several attempts were made us-
ing a purified Met ectodomain and recombinant HGF (reviewed
in [39]). Only a short part of the Met ectodomain was shown
to form a 2:2 complex in the presence of an HGF dimer while
Met928 did not [40]. That HGF could not induce Met dimeriza-
tion might be due to the fact that the Met truncated version used
for these assays lacked essential sequences for dimerization. For
example it is known that the transmembrane domain can stabilize
the dimers of several RTKs (reviewed in [41]). Dimerization of
Met might require other molecules than HGF. CD44v6 might be
such a candidate since it has been shown to be required for Met
phosphorylation, a direct consequence of the dimerization of the
intracellular tyrosine kinase domains of Met. It is possible that
CD44v6 and not CD44s allows Met to enter a stable homodimer
configuration. While both CD44v6 and CD44s had binding af-
finities to HGF in the same order of magnitude, MST, FCS and
FA all presented a 2–3 folds difference that might be relevant
for interactions with HGF in vivo. As we have shown in this
work, HGF is able to directly bind CD44v6 and Met and thus
HGF might bridge the two transmembrane proteins to allow a
protein complex arrangement necessary for Met dimerization. In
addition, the binding of CD44v6 to HGF might stabilize the very
weak dimerization of HGF itself, which is speculated to be the
prerequisite for Met dimerization [40].
Of note, the CD44v6 peptide prevented the binding of growth
factors to cells in FACS analysis and cellular ELISA. Since it
binds to the CD44v6 ectodomain but not to HGF, a possible mode
of action of this peptide is a competition with HGF for binding to
CD44v6. Indeed, we showed that the affinity of the CD44v6 pep-
tide for the CD44v6 ectodomain is several magnitudes higher than
the affinity of HGF for the CD44v6 ectodomain. The high affinity
of the CD44v6 peptide for the CD44v6 ectodomain might explain
its high efficiency in inhibition of tumour angiogenesis [15].
In conclusion, a non-HS isoform of the CD44 family,
CD44v6 directly binds to HGF and VEGF. The difference
between the binding affinities measured for HGF/CD44v6 and
VEGF165/CD44v6 and the fact that CD44s binds HGF but not
VEGF165 might however reflect a different mode of action
between Met and VEGFR-2 co-receptor function of CD44v6.
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